Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 18/20 | 0.61 |
| ▸ | ACHE | P22303 | 4/20 | 0.60 |
| ▸ | RAD52 | P43351 | 1/20 | 0.60 |
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3294008 | 0.84 | DRD2 (0.62) | DRD2SLC6A4 | |
| SCHEMBL3132276 | 0.80 | DRD2 (0.67) | ACHEDRD2SLC6A4 | |
| SCHEMBL3572587 | 0.78 | HRH3 (1.00) | HRH3ACHERAD52 | |
| Jnj-5207852 SCHEMBL3577334 | 0.78 | HRH3 (1.00) | HRH3ACHERAD52 | |
| SCHEMBL3580340 | 0.78 | HRH3 (1.00) | HRH3ACHERAD52 | |
| SCHEMBL3574322 | 0.77 | HRH3 (0.86) | HRH3ACHERAD52 | |
| SCHEMBL3578155 | 0.76 | CHRM1 (0.74) | HRH3ACHEDRD2 | |
| SCHEMBL3567760 | 0.76 | HRH3 (1.00) | HRH3ACHERAD52 | |
| SCHEMBL3577046 | 0.76 | HRH3 (1.00) | HRH3ACHERAD52SLC6A4 | |
| SCHEMBL31587416 | 0.76 | DRD2 (0.61) | DRD2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060235049-A1 | 1-{3-[4-(1-Methyl-pyrrolidin-2-yl)-phenoxy]-propyl}-piperidine, and 1-Benzyl-4-[4-(3-piperidin-1-yl-propoxy)-phenyl]-piperidin-4-ol; histamin receptor antagonist; antidepressant; upper airway allergies, nasal congestion, allergic rhinitis, cognitive dysfunction, schizophrenia, manic disorders | APODACA RICHARD | 2006-10-19 | — | — | US | claimed |
| EP-1313721-B1 | NON-IMIDAZOLE ARYLOXYALKYLAMINES AS H3 RECEPTOR LIGANDS | ORTHO MCNEIL PHARM INC (US) | 2006-03-08 | — | — | EP | claimed |
| EP-1313721-A2 | NON-IMIDAZOLE ARYLOXYALKYLAMINES AS H3 RECEPTOR LIGANDS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-05-28 | — | — | EP | claimed |
| US-20020065278-A1 | Non-imidazole aryloxyalkylamines | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2002-05-30 | — | — | US | claimed |
| WO-2002012214-A2 | NON-IMIDAZOLE ARYLOXYALKYLAMINES AS H3 RECEPTOR LIGANDS | ORTHO MCNEIL PHARMACEUTICAL INC. (US) | 2002-02-14 | — | — | WO | claimed |
| US-20100004241-A1 | NON-IMIDAZOLE ARYLOXYALKYLAMINES | JANSSEN PHARMACEUTICA NV (BE) | 2010-01-07 | — | — | US | disclosed |
| US-20100004241-A1 | NON-IMIDAZOLE ARYLOXYALKYLAMINES | JANSSEN PHARMACEUTICA NV (BE) | 2010-01-07 | — | — | US | disclosed |
| US-20100004241-A1 | NON-IMIDAZOLE ARYLOXYALKYLAMINES | JANSSEN PHARMACEUTICA NV (BE) | 2010-01-07 | — | — | US | disclosed |
| US-20080306085-A1 | NON-IMIDAZOLE ARYLOXYALKYLAMINES | APODACA RICHARD | 2008-12-11 | — | — | US | disclosed |
| US-20080306085-A1 | NON-IMIDAZOLE ARYLOXYALKYLAMINES | APODACA RICHARD | 2008-12-11 | — | — | US | disclosed |
| US-7429586-B2 | Non-imidazole aryloxyalkylamines | ORTHO-MCNEIL PHARMACEUTICLAS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429586-B2 | Non-imidazole aryloxyalkylamines | ORTHO-MCNEIL PHARMACEUTICLAS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-7186732-B2 | Non-imidazole aryloxyalkylamines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186732-B2 | Non-imidazole aryloxyalkylamines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186732-B2 | Non-imidazole aryloxyalkylamines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-20060235049-A1 | 1-{3-[4-(1-Methyl-pyrrolidin-2-yl)-phenoxy]-propyl}-piperidine, and 1-Benzyl-4-[4-(3-piperidin-1-yl-propoxy)-phenyl]-piperidin-4-ol; histamin receptor antagonist; antidepressant; upper airway allergies, nasal congestion, allergic rhinitis, cognitive dysfunction, schizophrenia, manic disorders | APODACA RICHARD | 2006-10-19 | — | — | US | disclosed |
| EP-1313721-B1 | NON-IMIDAZOLE ARYLOXYALKYLAMINES AS H3 RECEPTOR LIGANDS | ORTHO MCNEIL PHARM INC (US) | 2006-03-08 | — | — | EP | disclosed |
| EP-1313721-A2 | NON-IMIDAZOLE ARYLOXYALKYLAMINES AS H3 RECEPTOR LIGANDS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20020065278-A1 | Non-imidazole aryloxyalkylamines | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2002-05-30 | — | — | US | disclosed |
| WO-2002012214-A2 | NON-IMIDAZOLE ARYLOXYALKYLAMINES AS H3 RECEPTOR LIGANDS | ORTHO MCNEIL PHARMACEUTICAL INC. (US) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065278-A1 | Non-imidazole aryloxyalkylamines | HNMT, HRH2, HRH3 | HRH3 3/4885ACHE 506/4885RAD52 3855/4885 |
| US-20060235049-A1 | 1-{3-[4-(1-Methyl-pyrrolidin-2-yl)-phenoxy]-propyl}-piperidine, and 1-Benzyl-4-[4-(3-piperidin-1-yl-propoxy)-phenyl]-piperidin-4-ol; histamin receptor antagonist; antidepressant; upper airway allergies, nasal congestion, allergic rhinitis, cognitive dysfunction, schizophrenia, manic disorders | HRH4, HRH3, HRH2 | HRH3 2/4885ACHE 1411/4885RAD52 3816/4885 |
| US-20100004241-A1 | NON-IMIDAZOLE ARYLOXYALKYLAMINES | HNMT, HRH2, HRH3 | HRH3 3/4885ACHE 506/4885RAD52 3855/4885 |
| US-20080306085-A1 | NON-IMIDAZOLE ARYLOXYALKYLAMINES | HNMT, HRH2, HRH3 | HRH3 3/4885ACHE 506/4885RAD52 3855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.